NovaBay Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $9.03 Mil.
During the past 12 months, NovaBay Pharmaceuticals's average Total Assets Growth Rate was -46.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 21.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 12.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 14.10% per year.
During the past 13 years, NovaBay Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 99.90%. The lowest was -27.60%. And the median was 20.00%.
Total Assets is connected with ROA %. NovaBay Pharmaceuticals's annualizedROA % for the quarter that ended in Dec. 2023 was -150.16%. Total Assets is also linked to Revenue through Asset Turnover. NovaBay Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.34.
NovaBay Pharmaceuticals Total Assets Historical Data
The historical data trend for NovaBay Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
NovaBay Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovaBay Pharmaceuticals (AMEX:NBY) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
NovaBay Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
NovaBay Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Business Description
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBY has been successfully added to your 